1887
  1. Home
  2. Eurosurveillance
  3. Volume 30, Issue 46, 20/Nov/2025
  4. Article
Rapid communication Open Access
Like 0
Download

SDG 3: Antimicrobial resistance

Abstract

The emergence and spread of an extensively drug-resistant (XDR) lineage 4.8 cluster in Europe raises public health concerns. First reported in 2020 across Romania, Italy and the United Kingdom, this cluster progressed from multidrug-resistant (MDR) and pre-extensively drug-resistant (pre-XDR) to XDR, including resistance to pretomanid. Evidence of ongoing local transmission is available for Italy, where 10 cases were reported from 2021 to 2025. Strengthened whole genome sequencing-based surveillance is needed to inform timely, coordinated public health responses.

© Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Loading

Article metrics loading...

/content/10.2807/1560-7917.ES.2025.30.46.2500838
2025-11-20
2025-12-08
/content/10.2807/1560-7917.ES.2025.30.46.2500838
Loading
Loading full text...

Full text loading...

/deliver/fulltext/eurosurveillance/30/46/eurosurv-30-46-2.html?itemId=/content/10.2807/1560-7917.ES.2025.30.46.2500838&mimeType=html&fmt=ahah

References

  1. Kherabi Y, Skouvig Pedersen O, Lange C, Bénézit F, Chesov D, Codecasa LR, et al. Treatment outcomes of extensively drug-resistant tuberculosis in Europe: a retrospective cohort study. Lancet Reg Health Eur. 2025;56:101380.  https://doi.org/10.1016/j.lanepe.2025.101380  PMID: 40697337 
  2. Költringer F, Koreny M, Werber D, Heger F, Chalupka A, Schweiger S, et al. Cross-border investigation of a tuberculosis outbreak in Vienna linked to a multi-country cluster among foreign-born individuals, Europe, 2021 to 2025. Euro Surveill. 2025;30(33):2500565.  https://doi.org/10.2807/1560-7917.ES.2025.30.33.2500565  PMID: 40843522 
  3. Tagliani E, Anthony R, Kohl TA, de Neeling A, Nikolayevskyy V, Ködmön C, et al. Use of a whole genome sequencing-based approach for Mycobacterium tuberculosis surveillance in Europe in 2017-2019: an ECDC pilot study. Eur Respir J. 2021;57(1):2002272.  https://doi.org/10.1183/13993003.02272-2020  PMID: 32732329 
  4. Villa S, Tagliani E, Borroni E, Castellotti PF, Ferrarese M, Ghodousi A, et al. Outbreak of pre- and extensively drug-resistant tuberculosis in northern Italy: urgency of cross-border, multidimensional, surveillance systems. Eur Respir J. 2021;58(3):2100839.  https://doi.org/10.1183/13993003.00839-2021  PMID: 34049944 
  5. Alagna R, Cabibbe AM, Miotto P, Saluzzo F, Köser CU, Niemann S, et al. Is the new WHO definition of extensively drug-resistant tuberculosis easy to apply in practice? Eur Respir J. 2021;58(1):2100959.  https://doi.org/10.1183/13993003.00959-2021  PMID: 34215664 
  6. European Centre for Disease Prevention and Control (ECDC). The European Surveillance System (TESSy). Stockholm: ECDC; 2019. Available from: https://ecdc.europa.eu/en/publications-data/european-surveillance-system-tessy
  7. Zhou Z, Alikhan NF, Sergeant MJ, Luhmann N, Vaz C, Francisco AP, et al. GrapeTree: visualization of core genomic relationships among 100,000 bacterial pathogens. Genome Res. 2018;28(9):1395-404.  https://doi.org/10.1101/gr.232397.117  PMID: 30049790 
  8. Kohl TA, Utpatel C, Schleusener V, De Filippo MR, Beckert P, Cirillo DM, et al. MTBseq: a comprehensive pipeline for whole genome sequence analysis of Mycobacterium tuberculosis complex isolates. PeerJ. 2018;6(11):e5895.  https://doi.org/10.7717/peerj.5895  PMID: 30479891 
  9. Rausch T, Zichner T, Schlattl A, Stütz AM, Benes V, Korbel JO. DELLY: structural variant discovery by integrated paired-end and split-read analysis. Bioinformatics. 2012;28(18):i333-9.  https://doi.org/10.1093/bioinformatics/bts378  PMID: 22962449 
  10. World Health Organization (WHO). Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance, 2nd ed. Geneva: WHO; 2023. Available from: https://www.who.int/publications/i/item/9789240082410
  11. Kadura S, King N, Nakhoul M, Zhu H, Theron G, Köser CU, et al. Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid. J Antimicrob Chemother. 2020;75(8):2031-43.  https://doi.org/10.1093/jac/dkaa136  PMID: 32361756 
  12. Sonnenkalb L, Carter J, Spitaleri A, Iqbal Z, Hunt M, Malone K, et al. Deciphering Bedaquiline and Clofazimine Resistance in Tuberculosis: An Evolutionary Medicine Approach. bioRxiv. 2021;2021.03.19.436148.
  13. European Centre for Disease Prevention and Control (ECDC). Tuberculosis molecular surveillance status report, focusing on rifampicin and multi-drug resistance in the EU/EEA. Stockholm: ECDC; 2025. Available from: https://www.ecdc.europa.eu/en/publications-data/tuberculosis-molecular-surveillance-status-report-focusing-rifampicin-and-multi
  14. Walker TM, Merker M, Knoblauch AM, Helbling P, Schoch OD, van der Werf MJ, et al. A cluster of multidrug-resistant Mycobacterium tuberculosis among patients arriving in Europe from the Horn of Africa: a molecular epidemiological study. Lancet Infect Dis. 2018;18(4):431-40.  https://doi.org/10.1016/S1473-3099(18)30004-5  PMID: 29326013 
  15. Tagliani E, Cirillo DM, Ködmön C, van der Werf MJ, Anthony R, van Soolingen D, et al. EUSeqMyTB to set standards and build capacity for whole genome sequencing for tuberculosis in the EU. Lancet Infect Dis. 2018;18(4):377.  https://doi.org/10.1016/S1473-3099(18)30132-4  PMID: 29582760 
  16. Ghodousi A, Omrani M, Torri S, Teymouri H, Russo G, Vismara C, et al. Evaluating the efficacy of whole genome sequencing in predicting susceptibility profiles for first-line antituberculosis drugs. Clin Microbiol Infect. 2025;31(1):121.e1-5.  https://doi.org/10.1016/j.cmi.2024.09.024  PMID: 39341416 
  17. Denholm JT, de Vries G, Anthony R, Robinson E, Backx M, Laurenson IF, et al. Considering best practice standards for routine whole-genome sequencing for TB care and control. IJTLD Open. 2024;1(10):431-6.  https://doi.org/10.5588/ijtldopen.24.0320  PMID: 39398433 
  18. Zhang X, Martinez E, Lam C, Crighton T, Sim E, Gall M, et al. Exploring programmatic indicators of tuberculosis control that incorporate routine Mycobacterium tuberculosis sequencing in low incidence settings: a comprehensive (2017-2021) patient cohort analysis. Lancet Reg Health West Pac. 2023;41:100910.  https://doi.org/10.1016/j.lanwpc.2023.100910  PMID: 37808343 
  19. Mugwagwa T, Abubakar I, White PJ. Using molecular testing and whole-genome sequencing for tuberculosis diagnosis in a low-burden setting: a cost-effectiveness analysis using transmission-dynamic modelling. Thorax. 2021;76(3):281-91.  https://doi.org/10.1136/thoraxjnl-2019-214004  PMID: 33542086 
Tracking the evolution of an extensively drug-resistant cross-border Mycobacterium tuberculosis cluster, Europe, January 2016 up to August 2025: implications for European surveillance
<p class="citation"> <span>Citation style for this article:</span> <span class="meta-value authors"> <a href="/search?value1=Francesca+Saluzzo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Saluzzo Francesca</a>, <a href="/search?value1=Chiara+Sepulcri&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Sepulcri Chiara</a>, <a href="/search?value1=Alma+Zinola&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Zinola Alma</a>, <a href="/search?value1=Federico+Di+Marco&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Di Marco Federico</a>, <a href="/search?value1=Luca+Ragazzoni&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Ragazzoni Luca</a>, <a href="/search?value1=Marco+Rossi&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Rossi Marco</a>, <a href="/search?value1=Luigi+Codecasa&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Codecasa Luigi</a>, <a href="/search?value1=Daniela+Maria+Cirillo&option1=author&noRedirect=true" class="nonDisambigAuthorLink">Cirillo Daniela Maria</a></span>. Tracking the evolution of an extensively drug-resistant cross-border Mycobacterium tuberculosis cluster, Europe, January 2016 up to August 2025: implications for European surveillance. <a href="/content/ecdc">Euro Surveill.</a> 2025;30(46):pii=2500838. <a href="https://doi.org/10.2807/1560-7917.ES.2025.30.46.2500838" title="doi link" target="_blank">https://doi.org/10.2807/1560-7917.ES.2025.30.46.2500838</a> <span class="ES_Article_citation"> <span class="generated">Received</span>: 02 Nov 2025;&nbsp;&nbsp; <span class="generated">Accepted</span>: 18 Nov 2025 </span> </p>
/content/10.2807/1560-7917.ES.2025.30.46.2500838
/content/10.2807/1560-7917.ES.2025.30.46.2500838
Loading

Data & Media loading...

Supplementary data

Submit comment
Close
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error